Patents by Inventor Yajing Liu

Yajing Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250055731
    Abstract: A communication method includes generating a first sequence, where the first sequence is based on a complete complementary code set, the complete complementary code set is based on a Golay pair and a Hadamard matrix through a Kronecker product operation, and the first sequence is used for channel estimation; and sending the first sequence. In the method, use of a P-matrix is avoided in a process of constructing a plurality of streams of zero correlation sequences.
    Type: Application
    Filed: October 18, 2024
    Publication date: February 13, 2025
    Inventors: Zhengchun Zhou, Rui Du, Yajing Zhou, Xiaohu Tang, Chenchen Liu, Xiao Han
  • Patent number: 12203077
    Abstract: Provided are base editors containing a cytidine and a catalytically inactive version of Lachnospiraceae bacterium Cpf1 (LbCpf1). The new base editors have greatly improved editing efficiency and fidelity as compared to Cas9-based base editors, and have different editing windows.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: January 21, 2025
    Assignee: ShanghaiTech University
    Inventors: Jia Chen, Xingxu Huang, Li Yang, Bei Yang, Xiaosa Li, Ying Wang, Yajing Liu
  • Patent number: 12196753
    Abstract: A kit for detecting drug-resistant tuberculosis, includes: detection reagents, configured to perform quantitative detection on 17 serum metabolites of patients with tuberculosis, the 17 serum metabolites comprising: taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-tetrachlorophthalic anhydride, malotilate, fulvic acid, and L-neopterin.
    Type: Grant
    Filed: May 11, 2024
    Date of Patent: January 14, 2025
    Assignee: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong Huang, Yajing Liu, Yan Su, Chao Zhang
  • Patent number: 12134771
    Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Grant
    Filed: January 5, 2023
    Date of Patent: November 5, 2024
    Assignee: ShanghaiTech University
    Inventors: Yajing Liu, Shisheng Huang, Xingxu Huang
  • Patent number: 12123006
    Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: October 22, 2024
    Assignee: SHANGHAITECH UNIVERSITY
    Inventors: Yajing Liu, Shisheng Huang, Xingxu Huang
  • Publication number: 20240295555
    Abstract: A kit for detecting drug-resistant tuberculosis, includes: detection reagents, configured to perform quantitative detection on 17 serum metabolites of patients with tuberculosis, the 17 serum metabolites comprising: taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-tetrachlorophthalic anhydride, malotilate, fulvic acid, and L-neopterin.
    Type: Application
    Filed: May 11, 2024
    Publication date: September 5, 2024
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20240295569
    Abstract: A tuberculosis detection kit includes diagnostic reagents for 17 serum metabolites of patients with tuberculosis, the detecting reagent being used for quantitative detection of the 17 serum metabolites of the patients with tuberculosis, the 17 serum metabolites comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)).
    Type: Application
    Filed: May 11, 2024
    Publication date: September 5, 2024
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20240191339
    Abstract: Provided are a nanocomposite dielectric film material for energy storage prepared by vertical self-assembly of lead zirconate titanate (PZT) and magnesium oxide (MgO), and a preparation method thereof. The method includes: 1, preparing a PZT powder; 2, mixing the PZT powder with an MgO powder to obtain a uniformly mixed PM composite powder; and mixing the PM composite powder with a binder, and subjecting a resulting mixture to tableting and cold isostatic pressing to obtain a PM composite target blank; 3, sintering the PM composite target blank at a temperature of not higher than 900° C. to obtain a PM composite target; and 4, subjecting the PM composite target to pulsed laser deposition to form an epitaxial vertical self-assembly composite dielectric film; and subjecting the epitaxial vertical self-assembly composite dielectric film to annealing to obtain the film material.
    Type: Application
    Filed: November 28, 2023
    Publication date: June 13, 2024
    Inventors: Weiwei Li, Yajing Liu
  • Publication number: 20230358766
    Abstract: A set of serum metabolic biomarkers and detection kit for detecting tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)). The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The tuberculosis detection model based on the levels of the 17 metabolic biomarkers can achieve an area under the ROC curve of 99.5%, sensitivity of 98.2%, and specificity of 95.8% in detecting tuberculosis.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 9, 2023
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20230349900
    Abstract: A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 2, 2023
    Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.
    Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
  • Publication number: 20230313205
    Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Application
    Filed: January 5, 2023
    Publication date: October 5, 2023
    Applicant: ShanghaiTech University
    Inventors: Yajing LIU, Shisheng HUANG, Xingxu HUANG
  • Publication number: 20230219911
    Abstract: A compound represented by general formula (I) or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An application of the compound of general formula (I) in preparation of drugs for treating and/or preventing she-mediated diseases, especially an application in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, diabetes complications, diabetes-related diseases, fibrotic diseases, neurological and mental diseases, pain, and ulcer diseases, etc.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 13, 2023
    Inventors: Yanfang ZHAO, Zibin GAO, Yufei HAN, Shuo LI, Yunlei HOU, Huimin ZHANG, Sicong XU, Yanping SUN, Mingze QIN, Yongjun SUN, Yajing LIU, Ping GONG
  • Publication number: 20220372497
    Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 24, 2022
    Inventors: Yajing LIU, Shisheng HUANG, Xingxu HUANG
  • Patent number: 11481041
    Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: October 25, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Michael Francis Deily, Michael Gordon Oldani, Yajing Liu, David Paul Platt, David Michael Lane, Thomas Joseph Longo
  • Publication number: 20220259196
    Abstract: The present invention relates to a 2-aminopyrimidine compound shown in formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof, preparation methods for the 2-aminopyrimidine compound, and the pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutical composition comprising the compound. Substituents R1, R2, R3, R4, X, Y, Z, Q, m, and n have meanings given in the description. The present invention further relates to the application of the compound of formula I in the preparation of a medication for treating and/or preventing a malignant hematologic disease and other proliferative diseases.
    Type: Application
    Filed: July 1, 2020
    Publication date: August 18, 2022
    Applicant: Shenyang Pharmaceutical University
    Inventors: Yanfang Zhao, Yingxiu Li, Mingze Qin, Yunlei Hou, Yajing Liu, Ping Gong
  • Publication number: 20220249771
    Abstract: Methods and systems for estimating force and motor torque in a mechatronic system are provided herein. Such methods and system are suited for improved control of small-scale mechatronic system, particularly a syringe, valve, and cartridge loader or door opening/closing mechanism of a diagnostic assay system. The methods can compensate for friction and account for various second-order effects, thereby allowing for more accurate pressure estimation, thereby allowing improved syringe operation. The methods can further allow for improved estimation of force or motor torque to allow for improved control of an actuatable valve interfacing the sample cartridge and cartridge loader or door opening/closing system. Methods of calibrating such systems are also provided.
    Type: Application
    Filed: January 13, 2022
    Publication date: August 11, 2022
    Inventors: Rajesh Nerkar, Amrita Chimni, Yajing Liu, Janaki-rama Vegiraju, Ricahard J. Casler
  • Patent number: 11144092
    Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 12, 2021
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Anthony James Hewett, Katherine Margaret Bailey, Ketan R. Shah, Yajing Liu, Karsten Aagaard, Scott Jeffrey Korn, Christopher Alan Schafer, Cesar Ambriz Rios, Alex Sai Cheong Cheng
  • Publication number: 20200409414
    Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 31, 2020
    Inventors: Anthony James Hewett, Katherine Margaret Bailey, Ketan R. Shah, Yajing Liu, Karsten Aagaard, Scott Jeffrey Korn, Christopher Alan Schafer, Cesar Ambriz Rios, Alex Sai Cheong Cheng
  • Publication number: 20200354729
    Abstract: Provided are base editors containing a cytidine and a catalytically inactive version of Lachnospiraceae bacterium Cpf1 (LbCpf1). The new base editors have greatly improved editing efficiency and fidelity as compared to Cas9-based base editors, and have different editing windows.
    Type: Application
    Filed: August 28, 2018
    Publication date: November 12, 2020
    Inventors: Jia Chen, Xingxu Huang, Li Yang, Bei Yang, Xiaosa Li, Ying Wang, Yajing Liu
  • Publication number: 20200348762
    Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 5, 2020
    Inventors: Michael Francis DEILY, Michael Gordon OLDANI, Yajing LIU, David Paul PLATT, David Michael LANE, Thomas Joseph LONGO